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Abstract
Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been 
referred to as “combined (or mixed) hepatocellular-cholangiocarcinoma.” These tumors, although 
described over 100 years ago, have attracted greater attention recently because of interest in 
possible stem cell origin and perhaps because of greater frequency and clinical recognition. 
Currently, because of a lack of common terminology in the literature, effective treatment and 
predictable outcome data have been challenging to accrue. This article represents a consensus 
document from an international community of pathologists, radiologists, and clinicians who have 
studied and reported on these tumors and recommends a working terminology for diagnostic and 
research approaches for further study and evaluation.
Conclusion: It is recommended that diagnosis is based on routine histopathology with 
hematoxylin and eosin (H&E); immunostains are supportive, but not essential for diagnosis. 
(HEPATOLOGY 2018; 00:000-000).
A dichotomous classification of primary liver carcinoma (PLC) into either hepatocellular 
carcinoma (HCC) or peripheral, intrahepatic cholangiocarcinoma CCA (iCCA) is challenged 
by increasing recognition of malignant epithelial hepatic tumors that share features of both 
cell types.
Classical HCC and iCCA demonstrate hepatocytic or cholangiocytic differentiation, 
respectively, and can be considered to represent two ends in a spectrum of PLCs. The 
distinction is important clinically because treatment considerations differ for classic HCC 
and iCCA, particularly with regard to transplant options, localized ablative treatments and 
systemic chemotherapy, and for prognostication.
It is currently recognized that PLCs exist that do not neatly fit into either category of HCC or 
iCCA cytologically or architecturally. These carcinomas are, in fact, not a homogenous 
tumor type, but have been broadly categorized as “mixed” or “combined” HCC-
cholangiocarcinoma (CCA) (cHCC-CCA), or “biphenotypic” PLC. PLCs with mixed 
phenotypes have been reported for more than a century,(1) albeit with inconsistent 
nomenclature (Supporting Table S1). This lack of uniform terminology is likely attributed to 
the complex morphological and immunohistological diversity of these tumors, rather than 
their rarity, given that several large series have reported that mixed tumors represent 2%-5% 
of PLC.(2-6) Lack of uniform terminology has impeded systematic study of this important 
category of PLC. The most recent edition of the World Health Organization’s (WHO) 
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Classification of Tumors of the Digestive System(7) specified a classic form of cHCC-CCA 
(i.e., a single tumor with both differentiations, not a collision between separate HCC and 
iCCA) and three variants with stem cell features: “typical,” “intermediate cell,” and 
“cholangiolocellular” subtypes. Significant recent work has shown, however, that “stem cell” 
phenotypes can be demonstrated in many forms of PLC, and the WHO categories are not as 
clearly separable as once thought.(8,9) Furthermore, improvements in laboratory techniques 
to demonstrate hepatocytic and cholangiocytic differentiation have resulted in increasingly 
common recognition of a spectrum of PLCs with mixed differentiation, the biological 
significance—and impact on tumor classification, staging, prognosis, and treatment—of 
which remains to be determined.
For progress to be made in unraveling the biological behavior and natural history of these 
tumors, we must necessarily begin by agreeing on terminology to classify them. With the 
promises of advances in the molecular biology of PLCs, and the development of more 
specialized therapeutics on the horizon, standardized nomenclature is critical for appropriate 
clinical-radiological-molecular-pathological correlations. Thus, an international group of 
hepatic pathologists, radiologists, surgeons, and clinicians previously published in this area 
have worked to formulate proposed nomenclature for these heterogeneous carcinomas with 
the goals of (1) creating uniformity of histological approach for diagnostic and research 
purposes and (2) facilitating scientific studies.
Primary Liver Carcinoma, Not Classic HCC or iCCA: Diagnostic Categories
Included in this heterogeneous group of carcinomas are three types:
1. Those in which there are varying degrees of hepatocytic and cholangiocytic 
cytologies and architectures, either admixed or as separate areas within the same 
tumor, referred to as cHCC-CCA.
2. PLC purely comprised of “intermediate cells,” referred to as intermediate cell 
carcinoma. These rare tumors contain relatively monomorphic populations of 
malignant epithelial cells that are phenotypically neither classic HCC nor classic 
iCCA. Immunophenotypically, they display variably mixed hepatocytic and 
cholangiocytic markers on a cellular basis.
3. PLC comprised of cholangiolocarcinoma (CLC).
Examples of each are illustrated in Supporting Fig. S1. Whether intermediate cell carcinoma 
and CLC are best categorized within cHCC-CCA, or as unique and separate entities,(10-12) 
has yet to be fully determined. However, it is now recognized that stem/progenitor cell 
features and desmoplastic stromal alterations may be detected in many PLCs; thus, these 
features are no longer considered characteristic of unique, specific diagnostic subtypes of 
cHCC-CCA.
Finally, all PLCs, including classic HCC and iCCA, cHCC-CCA, intermediate cell 
carcinoma, and CLC, have been reported to occur alone or in combination with one 
another(8,9) (Fig. 1).
Brunt et al. Page 3
Hepatology. Author manuscript; available in PMC 2019 January 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fibrolamellar HCC is a distinct, unique PLC that has yet to be reported as a component in 
“combined” tumors; thus, it will not be further discussed in this consensus document. 
Further caveats for this nomenclature apply; cHCC-CCA is not considered appropriate 
terminology for:
• distinct (multifocal) HCC and iCCA;
• collision tumors of HCC and iCCA arising separately in the same liver;
• any form of hepatoblastoma or variants, such as those with cholangiocytic or 
ductal plate components;
• the pediatric “transitional liver cell tumor” or variants (13);
• morphologically typical HCCs with only immunohistochemical expression of 
keratin (K)19 or other cholangiocytic or stem/progenitor cell markers;*
• morphologically typical iCCAs with only immunohistochemical expression of 
hepatocytic or stem/progenitor cell markers, or iCCA with in situ hybridization 
markers for hepatocytic differentiation (i.e., albumin)†; and
• sclerosing/scirrhous HCC, a rare variant of HCC with some areas that may be 
suggestive of iCCA (adenocarcinoma in sclerotic stroma).
Diagnostic Terminology of cHCC-CCA
Important considerations for diagnostic categorization of mass lesions in the liver include 
knowledge of sex and background liver disease, as well as adequacy of tissue sample. 
cHCC-CCA have been reported in both cirrhotic and noncirrhotic livers,(6,16,17) in contrast 
to HCC which is significantly more common in cirrhosis, and iCCA, which is more common 
in patients without cirrhosis. No sex distinction has been found in cHCC-CCA.
In an appropriately sectioned and sampled resection specimen, there is a high likelihood of 
visualization and correct characterization of all components. Biopsy-based tissue samples 
are common for diagnosis and tumor characterization, such as molecular profiling, but may 
not contain salient tumor components, and intratumoral heterogeneity of most cHCC-CCA 
can lead to incorrect diagnosis if a biopsy does not contain adequate tissue. Exactly what an 
“adequate” biopsy should be is an area that will require multi-institutional collaborative 
discussion. But the importance of recognizing the risk of “sampling error” cannot be 
overstated particularly when radiographical features are not uniformly typical for classic 
HCC.
It remains the consensus of this international group that histopathological diagnoses of PLCs 
are based primarily on routine stains (i.e., H&E ± histochemical stains for matrix proteins or 
mucins); immunohistochemical stains are secondary, providing supplemental evidence. It is 
also now recommended there should no longer be formal diagnostic subtypes based on the 
*HCC with expression of K19 in >5% of tumor cells have a worse prognosis than HCC without this immunophenotype staining, 
however, is usually not within an area with stem/progenitor cell morphology, but in tumor cells that are clearly hepatocytic. Published 
data regarding other stem cell markers and similar thresholds for “positive” are still less robust.(14)†mRNA in an iCCA is not necessarily reflective of protein production.(15)
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identification of stem/progenitor cells, but rather if stem/progenitor cell features are 
observed, they are noted in a comment as “stem/progenitor cell features present.” 
Furthermore, if combinations of PLC are present, it is recommended the diagnostic 
terminology include which forms of PLC are “combined” (e.g., cHCC-CCA; cHCC-CLC; 
ciCCA-CLC, cHCC-CCA-CLC, cHCC-CCA-intermediate cell ca, etc.). Some investigators 
recommend reporting percent of each component present,(18) even in biopsy samples, 
although the challenges of this are recognized. Supporting Table S2 compares descriptive, 
WHO 2010, and this proposed terminology.
Microscopic Pathology
As the nomenclature indicates, cHCC-CCA contains areas of both typical HCC and typical 
iCCA, the former having any/all of the possible cytological and architectural features of 
HCCs and the latter distinctly being an adenocarcinoma with malignant glands, usually lying 
within a dense stromal background (Fig. 2). The two components may be intermixed, or lie 
in separate regions of a tumor, though focal areas of merging can often be discerned. At the 
current time, there are no published consensus guidelines for minimum amounts of HCC or 
iCCA to qualify for the diagnosis, either in biopsy material or in resected/explant samples. 
Examples have been illustrated.(7-9,18-22) In regions in which the tumors seem to merge, the 
cellular morphology may be difficult to identify as either hepatocellular or cholangiocytic by 
pure H&E evaluation alone. Tumor cells of either hepatocytic or cholangiocytic 
morphologic type may contain intracytoplasmic inclusions common to hepatocytes such as 
Mallory-Denk bodies, steatosis, α1AT globules (even in an α1AT genotypically normal 
individual), fibrinogen, etc. Mucin stains, if utilized, are most often negative.
“STEM/PROGENITOR CELL” FEATURES/PHENOTYPES
Stem/progenitor cell features or phenotypes can be observed by both light microscopy and 
immunohistochemistry (IHC), however, in and of themselves, are not taken as proof of 
origin of carcinoma. These features/ phenotype consist of small cells with scant cytoplasm, a 
high nuclear/cytoplasmic ratio, and hyperchromatic nuclei (Fig. 3A). These cells are most 
often found at the interface between a nest of carcinoma and the adjoining tumoral fibrous or 
desmoplastic stroma.(23) Mitotic activity is uncommon. Lineage-like progressions may be 
noted by routine stains from the small cells at the periphery (those with stem/progenitor 
features) to more differentiated neoplastic hepatocytes or glands within the nests. Tumor 
cells may be variably highlighted by IHC for stem/progenitor markers, such as, but not 
limited to, keratin (K)19, cluster of differentiation (CD)56, epithelial cell adhesion molecule 
(EpCAM), ckit (aka, cluster of differentiation, CD117), and others.(22,24)
INTERMEDIATE CELL CARCINOMA
Intermediate cell carcinoma has been inconsistently described.(9,19,20) However, with 
growing evidence of the presence of such a lesion,(7-9) the term is applied to carcinomas in 
which a monomorphic tumor is comprised of tumor cells smaller than normal hepatocytes, 
but larger than the above-described stem/progenitor cell phenotype, and have features 
intermediate between hepatocytes and cholangiocytes (Fig. 3B). The tumor cells may be 
cuboidal to oval-shaped, with pale or pink cytoplasm. Tumor cells may be arranged in 
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trabeculae, or cords, solid nests, or strands, and set within a background of marked 
desmoplastic or acellular hyalinized stroma. Elongated, ill-defined gland-like structures may 
be present, suggestive of tubules, but well-defined glands are not observed. Tumor cell 
atypia and mitoses are uncommon. Mucin production is absent. Supportive IHC displays 
some features of both hepatocytic and cholangiocytic lineage within individual cells.(22)
The entire tumor is commonly comprised of intermediate cells, and when present in a 
desmoplastic stroma, this tumor may be misdiagnosed as iCCA. Tumor nests, on the other 
hand, may appear as HCC. Intermediate cell carcinomas have been reported to have typical 
invasive patterns of spread of both HCC (intravascular and intrabiliary) and iCCA 
(lymphatic and perineural).
CLC
CLC (aka, cholangiolocellular carcinoma), first described in 11 African cases by Steiner and 
Higginson in 1959,(25) was conjectured to arise from cells within the canal of Hering. It 
remains as an incompletely understood form of PLC. Although both CLC and iCCA have 
bililary features, studies to date have shown clinicopathological, radiological, and molecular 
characteristics distinct from both iCCA and HCC(10,11,26-30) (Fig. 3C). CLC may comprise 
the entire PLC, or variably as a component of an HCC, an iCCA,(31) or as a component in a 
cHCC-CCA. The conventionally accepted criteria for CLC being the “sole component” of 
PLC is that >80% of tumor consists of CLC. This implies, however, that the entire lesion has 
been removed and histologically sampled. By microscopic locale and by histology, CLC 
closely resembles the epithelial components of a “ductular reaction,” because it appears to 
arise near and/or surround residual portal tracts. CLC consists of thin, malignant ductular-
like structures that may appear to radiate from or surround a portal tract in a tubular, cord-
like, anastomosing pattern (“antler-like” pattern) within a dense, hyalinized stroma. The 
tumor may show trabecular and replacing growth at its interface with the surrounding 
nontumorous liver. Although these latter architectural features may be suggestive of HCC, 
they are not by themselves sufficient evidence of a hepatocellular phenotype and may also 
occur in typical iCCA. CLC is mucin negative. Immunohistochemically, CLC demonstrates 
characteristic luminal reactivity with antibodies to epithelial membrane antigen(30) and 
polyclonal CEA (pCEA), which contrasts with the cytoplasmic positivity of iCCA with 
these antibodies.(27,29) There may be a range of differentiation patterns within CLC, and a 
rare variant with spindle cell pattern has been reported.(30)
Whether CLC is the sole diagnosis, or only a component of another PLC, its presence and 
percent amount may be useful information to document in the pathology report. The recent 
study of Rhee et al.(31) indicates that iCCA containing CLC in a portion of tumor with a 
CLC differentiation trait, confirmed by molecular and IHC investigations, carries a better 
prognosis than iCCA without it.
IHC of PLC
IHC is best considered a supplement for PLC, inclusive of cHCC-CCA, intermediate cell 
carcinoma, and CLC, but IHC should not define the diagnosis, in and of itself, and requires 
expertise in interpretation. The uses of IHC in PLC have been summarized.(18,22) The 
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markers can be divided into those characteristic of hepatocytes (hepatocyte in paraffin 1), 
alpha fetoprotein (AFP; pCEA [canalicular], CD10 [canalicular], arginase-1, and 
glypican-3), and biliary cells (pCEA [cytoplasmic and/or membranous], CD10 
[cytoplasmic], and K7 and K19). Malignant transformation may alter expression of these 
markers, and familiarity with them in settings of malignancy is recommended.
The use of markers for “stem/progenitor cell” features/phenotypes in cHCC-CCA can be 
challenging. Because at least some stem/progenitor cell niches in the liver are located within 
the biliary tree, their immunophenotypes overlap with cholangiocytic markers. Therefore, 
some “stem/progenitor cell markers” such as EpCAM and K19 are markers of 
cholangiocytes in various stages of development. Interpretation of these markers should thus 
rely primarily on morphological characteristics of the positive cells. If these cells have the 
morphological characteristics of cholangiocytes and form ductules or glands, they should be 
regarded as cholangiocytes. If, on the other hand, the cellular morphology of the reactive 
cells is that of stem/progenitor cells, they can be considered to represent stem/progenitor 
cells. At the other end of the spectrum, CD117 (c-kit), CD133, and others(24) are not 
diffusely expressed throughout the biliary tree and therefore can be considered markers that 
represent “stemness.” CD56 (aka neural cell adhesion marker) lies somewhere in between 
this spectrum because, while not staining the entire biliary tree, it often stains the full extent 
of ductular reactions. As with EpCAM and K19, interpretation of CD56 is therefore best 
based on the cellular morphology of the positive cells.
Molecular Pathology OF cHCC-CCA
Although limited in number, molecular studies have highlighted significant heterogeneity in 
cHCC-CCA at the molecular level.(10,32) The most recent studies have identified a group of 
cHCC-CCA displaying expression of stemness features. Indeed, using a genome-wide 
transcriptional analysis, Coulouarn et al.’s study(32) exhibited stem/progenitor features 
associated with down-regulation of the hepatocyte differentiation program and a 
commitment to the biliary lineage in a series of 20 cHCC-CCA histologically belonging to 
the type with stem cell features. This result was confirmed in a recent integrative genomic 
analysis performed in formalin-fixed paraffin-embedded samples from 18 cHCC-CCA 
representative of the different tumor subtypes of cHCC-CCA, revealing stem cell subtype 
characterized by spaltlike transcription factor 4 expression, enrichment of progenitor-like 
signatures, and activation of MYC and insulin-like growth factor pathways.(10)
In addition, CLC is suggested to be unique, showing low chromosomal instability, 
enrichment of transforming growth factor beta (TGF-β) signaling, and biliary cell lineage 
markers, as compared to other sub-types.(10,32) Such results are in accord with previous data 
comparing loss of heterozygosity using 400 microsatellite markers, p53, and β-catenin 
mutations in a series of 15 cHCC-CCAs with 9 iCCAs, and 137 HCCs, suggesting that 
cHCC-CCA were genetically closer to iCCA than to HCC.(33) TGF-β and Wnt/β-catenin 
were identified as the two major signaling pathways involved in cHCC-CCA.(32) 
Interestingly, increase in TGF-β-signaling pathway has also been reported in a subset of 
HCC characterized by the presence of prominent fibrous stroma, namely “scirrhous HCC,”
(34)
 as well as CLC,(10) and could be attributed to the presence of the tumoral fibrous stroma.
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Whereas the identification in cHCC-CCA of common molecular traits with more aggressive 
HCC and iCCA is now well established, significant attention should be paid in respect to the 
background nontumoral liver, which could have a strong impact on the liver’s mutational 
landscape.(35) Indeed, in Fujimoto et al.’s study,(35) a whole-genome sequencing analysis 
performed on 30 PLCs displaying biliary phenotype, including 7 cHCC-CCAs, 2 CLCs, and 
21 iCCAs, showed that the genome-wide substitution patterns regardless of tumor type 
arising in a background of chronic hepatitis overlapped with those of 60 HCCs, whereas 
those of arising within hepatitis-negative livers diverged from HCC. In addition, mutations 
of KRAS and IDH genes were more frequent in the hepatitisnegative tumors, whereas the 
TERT promoter mutation was more frequent in cHCC-CCA and HCCs, which mainly 
developed in a background of chronic hepatitis.
The molecular signature of stemness in cHCC-CCA has supported the concept of a stem/
progenitor cell origin of cHCC-CCA.(14,23,36) Although this concept is still debated, it 
implies the notion of clonality, for which no consensus has been reached to date.(37) 
Nevertheless, a clonal origin has been successfully demonstrated in a subset of cHCC-CCA 
(8 of 11 cases) by studying allelic status of a number of selected chromosomes’ arms 
following laser microdissection.(38) Clonality is further supported by the demonstration of 
significant correlation in the copy number variation between iCCA and HCC components of 
the classical type of cHCC-CCA.(10) The presence of a stemness molecular signature is 
usually viewed, and confirmed in a recent small series as an adverse prognostic factor in 
hepatic malignancies.(10) Whereas the worse prognosis for HCC with K19 positivity has 
been well demonstrated,(14,36,39-41) there is good prognostic evidence from two recent Asian 
clinicopathological studies for CLC: One compared CLC to iCCA(11) and another compared 
ciCCA-CLC to iCCA without CLC.(31) Nevertheless, a worse postoperative survival rate has 
been reported in the group of cHCC-CCA exhibiting >5% stem cells.(42) Moreover, cHCC-
CCA has been recently shown to have a larger “side population” of tumor cells, which 
implies more chemoresistance of these tumors compared to classical HCC and HCC 
expressing K19.(43)
Radiology
In contrast to classical HCC and iCCA, there are few publications that describe the 
radiological appearances of cHCC-CCA. Additionally, the relative infrequency of these 
lesions, the evolving pathological definition, and inconsistent use of radiology terminology, 
provide formidable challenges to accurate analysis of the existing literature. In single-center, 
retrospective case reports and series, cHCC-CCA are described as demonstrating some form 
of arterial hyperenhancement (APHE), most commonly peripheral or rim-like, on dynamic 
contrast-enhanced magnetic resonance imaging (MRI) and computed tomography (CT; 
Table 1).(6,16,17,27,44-51) Washout appearance is common and is often peripheral in location. 
Delayed central enhancement is frequently observed. These imaging features most 
commonly overlap with those of iCCA(17,48) (Fig. 4). Rarely, cHCC-CCA may resemble 
classical HCC (Fig. 4), by displaying diffuse APHE and diffuse or patchy washout 
appearance, or have features of both classical HCC and iCCA (Fig. 5).(16,44,50) Imaging 
features that are preponderantly HCC or iCCA appear to correspond to the predominant 
histopathology component of HCC and iCCA respectively(44,50) Discordance of tumor 
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markers with imaging appearances (i.e., elevated CA19-9 in a lesion resembling an HCC or 
elevated AFP in a lesion more resembling iCCA) provide another clue to accurately identify 
cHCC-CCA(6,16,17) (Fig. 6). Imaging may also be used to target the biopsy needle to specific 
HCC-like and iCCA-like areas in the cHCC-CCA tumor.
In a single-center retrospective study,(45) most (93.5%) cHCC-CCAs were categorized as an 
unknown liver malignancy (LR-M; probably malignant, not specific for HCC) using the 
American College of Radiology’s liver imaging reporting and data system (LI-RADS).(52) 
However, unlike the majority of HCCs, cHCC-CCA may arise in patients without cirrhosis 
or other known risk factors for HCC, as noted above, thus placing them outside of the 
context of LI-RADS and other similar diagnostic systems, which were formulated for the 
diagnosis of HCC in at-risk populations.(53) No studies have compared the biological 
behavior or imaging appearance of cHCC-CCA arising in patients with versus without 
cirrhosis or other HCC risk factors.
Translation of cHCC-CCA into the Clinic: Next Steps
This consensus document hopes to represent substantial progress in standardizing the 
pathological definition and diagnosis of cHCC-CCA and to be of use to clinical and research 
pathologists, hepatologists, surgeons, radiologists, and oncologists. The document provides a 
platform for future clinical and translational investigations regarding cHCC-CCA, an 
increasingly recognized malignancy. Although little is known clinically about these cancers, 
the data available suggest they are aggressive and likely signify a unique subset of primary 
liver cancers, which merit clinical distinction.
cHCC-CCA is important to characterize because a major source of clinical uncertainty are 
mass lesions in advanced stage (cirrhotic) liver that do not demonstrate radiological features 
typical for HCC. The LI-RADS criteria for diagnosing HCC are predicated on a high 
specificity of the radiographical findings, rather than sensitivity. In theory, the combination 
of specific imaging features and an appropriate pretest probability (i.e., applied in the at-risk 
population) allow sufficiently high specificity to obviate the need for biopsy. Thus, in the 
appropriate setting and with typical radiological features of HCC, a confident diagnosis can 
be made without biopsy.
However, for lesions that do not meet these stringent criteria (no established clinical risk 
factors, atypical imaging features), LI-RADS suggests biopsy as a possible appropriate 
diagnostic pathway. Many of these may turn out to be HCC upon biopsy, but some may not. 
These are lesions best described by the LI-RADS category LR-M, probably or definitely 
malignant but not specific for HCC.
The challenges associated with imaging cHCC-CCA raise two immediate areas that require 
investigation. The first regards the means of making the diagnosis of cHCC-CCA: If tumors 
are radiologically heterogeneous, how many areas must be biopsied to have confidence of a 
complete assessment of the nature of the malignancy and what are the appropriate methods 
and criteria to target those biopsies? Correlation between preresection imaging and resected 
tumors, mapping the pathology to the radiology in detail, will play an important role. The 
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second challenge regards the management of cHCC-CCA in cirrhosis, once diagnosed: (1) 
What is the outcome with liver transplantation?; (2) How do these cancers respond to 
locoregional therapies, particularly when bridging patients to liver transplantation?; and (3) 
How do these tumors respond to systemic therapies traditionally given for HCC or iCCA, in 
particular, the newer targeted agents? These are urgent questions that need to be addressed 
with more abundant data than published in small series to date.(54,55)
A recent study, the first to analyze recurrences and metastases after identification of a 
primary cHCC-CCA, indicates that just as the primary tumors are undoubtedly 
heterogeneous, the recurrent and metastatic lesions are as well.(56) Mixed tumors reflective 
of the primary may be observed in recurrence or metastases, or an individual component of 
the original may metastasize. Different single components even have unique organ tropisms. 
This study, the first of its kind and only 4 cases, is sufficient, however, to reaffirm the need 
for multi-institutional collaborative work to study the natural history of recurrence and 
spread of combined PLC.
What are other next steps to establish the clinical-pathological relevance of cHCC-CCA as a 
distinct entity even in the absence of cirrhosis? First, the interobserver variability for this 
pathological definition needs to be rigorously and robustly examined. It will be impossible 
to make progress if the diagnosis of cHCC-CCA cannot be standardized across institutions. 
Second, continued molecular profiling of well-defined cHCC-CCA needs to be performed; 
we need to know whether these tumors are associated with unique genetic signatures, 
genetic aberrations, or epigenetic markers. Given their phenotypic diversity by pathological 
evaluation, it is possible that the genetic profiles of cHCC-CCA are even more 
heterogeneous than classic HCC or iCCA. In fact, it is possible that, if cHCC-CCA have a 
high mutational burden, they may be more responsive to immunotherapy than other PLC. 
Third, outcomes data for surgical resection, liver transplantation, locoregional therapy, and 
systemic agents need to be examined and compared to classic HCC and iCCA for clinical, 
pathological, and radio-graphical factors for potential prognostic and predictive values. We 
need to know whether cHCC-CCA should be treated as HCC or iCCA or as a completely 
different tumor entity. Fourth, the question of whether locoregional therapy can drive a 
classic HCC to exhibit the phenotypic morphology of cHCC-CCA, as reported(57) needs 
clarification. For example, is the presence of angular glands on the periphery of presumed 
HCC lesions treated by transarterial chemoembolization (TACE) a treatment effect 
representing change in the cancer’s phenotype or were these cancers cHCC-CCA prior to 
TACE, or does TACE simply unmask the complexity of these tumors?(57) Of course, these 
questions are difficult to assess in the absence of pretreatment biopsies. This issue returns us 
to the questions of biopsies: how many, and how they should be targeted if an untreated 
lesion shows atypical imaging. It also raises the issue of whether radiology is truly 
sufficient, without confirmatory biopsy, for excluding iCCA, or other components of cHCC-
CCA in the first place. Fifth, as exemplified by recent changes in the American Joint 
Committee on Cancer Tumor Node Metastasis staging criteria for intra- and extrahepatic 
biliary tract cancers,(58) we need to better understand how cHCC-CCA tumors should be 
staged. Finally, none of these questions can be answered by a single institution given that 
these cHCC-CCA likely comprise ~2% of all primary liver cancers. Consortia of 
investigators will need to be formulated to efficiently and correctly address these and other 
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questions. This consensus document therefore represents the first of many steps toward an 
understanding of these forms of PLC. Table 2 provides current Practice Points based on this 
consensus document.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Abbreviations:
AFP alpha fetoprotein
APHE arterial phase hyperenhancement
CCA cholangiocarcinoma
cHCC-CCA combined (or mixed) hepatocellular-cholangiocarcinoma
CLC cholangiolocarcinoma
CT computed tomography
EpCAM epithelial cell adhesion molecule
HCC hepatocellular carcinoma
H&E hematoxylin and eosin
iCCA intrahepatic cholangiocarcinoma
IHC immunohistochemistry
K keratin
MRI magnetic resonance imaging
pCEA polyclonal CEA
PLC primary liver carcinoma
TACE transarterial chemoembolization
TGF-β transforming growth factor beta
WHO World Health Organization
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FIG. 1. 
Differentiative and histological relationships between PLCs. PLCs show an array of 
differentiative states from hepatocytic (left) through combined types (middle) to 
cholangiocytic (right). Thus, there are classic HCCs that are morphologically only 
hepatocytic, some of which, however, display immunophenotypes, including cholangiocytic 
marker antigens (e.g., K19). There are also classic iCCAs that are morphologically pure 
adenocarcinomas, some of which may display immunophenotypes of hepatocytic marker 
antigens or mRNA. In the middle are the cHCC-CCAs—these are histologically partly 
morphological HCC and partly morphologically iCCA; immunophenotyping of such lesions 
can be helpful in confirming the histological impression, but morphology remains the 
primary criterion. CLC is a separate form of generally lower-grade biliary malignancy. CLC, 
as indicated, may be found in combination with any of the other forms of PLC in the 
diagram. Intermediate cell carcinoma is also distinctive: For this tumor, the morphology is 
neither that of HCC nor that of iCCA, but the mixture of cholangiocytic and hepatocytic 
features is observed on a cell-by-cell basis on the basis of immunophenotyping. Thus, for 
this tumor type alone, morphology requires confirmatory immunophenotyping to 
demonstrate the mixture of differentiation markers.
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FIG. 2. 
Combined HCC-CCA, defined by histochemical staining. A 67-year-old man with chronic 
hepatitis B and cirrhosis. Imaging diagnosis of a 3-cm hypervascular nodule in segment VII 
resulted in the segmentectomy specimen illustrated. (A) Gross evaluation shows a well-
demarcated, lobulated tumor with two grossly distinct areas, labeled {1} and {2}. {1} is 
whiter and firmer while {2} is smoother and more yellow. (B) At low magnification, H&E 
evaluation shows that {1} is densely packed basophilic cells and {2} has more apparent 
nests of tumor cells within a fibrous stroma. (H&E, ×10). (C) Higher magnification of 
component {1} shows small tumoral cells arranged in glandular structures consistent with 
cholangiocytic differentiation. (D) is a higher magnification of component {2}, which is 
composed of nests of larger, eosinophilic cells with round nuclei and focally prominent 
nucleoli consistent with hepatocellular differentiation (C,D; H&E, ×20). IHC was positive 
for K7 and EpCAM in both tumor components. Positive K19, Glypican 3, and AFP staining 
were primarily in component {2}. Around 10% of cells were CD56 positive, preferentially 
in component{1}.
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FIG. 3. 
Morphological variants of stem/progenitor cell features. (A) HCC with stem cell/progenitor 
cell features. Nests of obvious hepatocytic tumor (often with little atypia) surrounded by 
stroma at the interface within which there are small cells with dark nuclei and high nuclear: 
cytoplasmic ratio (H&E, ×20). (B) Intermediate cell carcinoma with cords and trabeculae of 
cells with “intermediate” size between hepatocytes and cholangiocytes, without clear gland 
formation, often in a desmoplastic stroma. This tumor may be mistaken for iCCA. (H&E, 
×20). (C) CLC in which slender, malignant ductules are present in a tubular, cord-like, 
anastomosing (“antler-like”) pattern within a dense stroma (H&E, ×20).
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FIG. 4. 
A 73-year-old woman with abdominal pain and lesion detected on imaging. Arterial phase, 
portal venous, and early and late delayed phase postcontrast magnetic resonance images (A-
D) show a large mass in the central liver encasing the inferior vena cava (IVC; arrows). Note 
the progressive enhancement on the dynamic postcontrast images using an extracellular 
contrast agent. There are some regions of peripheral washout on the second delayed image 
(open arrow). The lesion shows T2 hyperintensity (E), no intralesional lipid or blood (F,G), 
and target appearance on diffusion weighted imaging/apparent diffusion coefficient (H,I, 
open arrow). The overall pattern is most compatible with a non-HCC malignancy, such as 
iCCA. The patient’s tumor markers were elevated (AFP-37,197 ng/mL and CA19-9-2168). 
Resection of the mass showed fairly uniform population of large tumor cells with abundant 
cytoplasm and large nuclei and nucleoli and brisk mitotic activity. The cells were arranged in 
solid nests and within lymphovascular spaces with no glandular formation. The IHC showed 
heterogeneous cell populations. AFP highlighted a majority of tumor cells whereas the 
hepatocyte-specific antigen showed only scattered positivity. Further IHC showed 
canalicular pCEA, diffuse K7 and K19 positivity, thyroid transcription factor-1, and K20 
negativity.
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FIG. 5. 
A 66-year-old woman at risk for HCC, with lesion detected on surveillance imaging. 
Precontrast, arterial phase, portal venous phase, and early and late delayed phase magnetic 
resonance images show a segment 5 hepatic lesion with mild central nodular arterial phase 
hyperenhancement followed by washout and capsule appearance on the delayed images 
using an extracellular contrast agent (arrows). This is a pattern most compatible with HCC. 
The lesion is mildly T2 hyperintense (F) and shows no intralesional fat or blood products 
(G,H). Tumor markers were negative. Biopsy of the lesion demonstrated moderately 
differentiated HCC with central hemorrhage and necrosis. Several tumor nodules were 
embedded fibrous stroma and IHC showed diffuse K7 and K19, weak nuclear p53, and 
canalicular pCEA.
Brunt et al. Page 20
Hepatology. Author manuscript; available in PMC 2019 January 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIG. 6. 
A 77-year-old woman with incidentally detected liver lesion. Arterial, portal venous, and 
early and late delayed magnetic resonance images obtained with an extracellular contrast 
agent at two slice positions (A-D and E-H) demonstrate a mixed enhancement pattern with 
features of both HCC and other malignancy. Arrows indicate a region of progressive 
enhancement along the medial border, which would be more compatible with iCCA. Open 
arrows indicate a region demonstrating washout and capsule appearance as observed in 
HCC. Diffusion weighted, apparent diffusion coefficient, in-phase, opposed phase, and fat 
suppressed T2 weighted images (I-M) also show a mixed picture. The arrows indicate a 
region of T2 hypointensity and different diffusion pattern. The in- and opposed-phase 
images demonstrate no intralesional blood products or fat. The overall picture would be 
indeterminate by imaging, not meeting algorithmic criteria for HCC. Tumor markers were 
all negative. Biopsy of the mass demonstrated a moderately differentiated primary liver 
carcinoma with morphological features of HCC (cells with abundant eosinophilic 
cytoplasm) and gland forming iCCA. IHC stains showed positivity for K7 and K19 and 
canalicular pCEA.
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TABLE 2.
Practice Points Summary
• The proposed terminology of primary liver carcinomas with both hepatocellular and cholangiocytic differentiation within the same tumor is 
combined hepatocellular-cholangiocarcinoma, cHCC-CCA.
• The diagnosis of cHCC-CCA relies on routine histochemical stains; IHC is used as a supplemental diagnostic tool.
• Stem cell phenotypes/features may exist within cHCC-CCA, and can be noted in a descriptive report. The finding does not warrant a separate 
subclassification.
• Two other types of PLC discussed include CLC and intermedate cell carcinoma. Both may coexist with HCC, iCCA, or cHCC-CCA.
• As molecular advances in all PLC, including cHCC-CCA are progressing, the importance of pathological confirmation of tumor type under 
study cannot be overemphasized.
• Radiological findings ofcHCC-CCA to date indicate features between those of typical HCC and iCCA, but often are not specific for either. 
Biopsy confirmation may be indicated.
• Radiological evidence of different components with different imaging features within a single tumor raises the as yet unanswered question of 
whether to biopsy each distinct region for accurate assessment.
• Clinical advances in patient management are occurring as the recognition of these tumors, both in cirrhosis and in noncirrhotic livers, grows. 
The exact incidence and prevalence in different diseases and in different clinical settings remain in question, partially attributed to terminology 
differences.
• It may be beneficial to establish an international registry with centralized pathology and radiology for further clinical study of these tumors.
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